Table 4.

Results of Menopausal Index assessment of two groups of perimenopausal women (n=18) according to Kupperman questionnaire: One group (PP-MM sequence) receiving for two months daily dose of 2 g (two 500 mg capsules twice daily) of Placebo (PP), followed by crossover (X) after which identical daily dose of Maca-GO (MM) was administered for another two months period (Treatment A - without prior run-in period), and the second group (MM-PP sequence) treated with identical daily doses of Maca-GO for two months followed by crossover and two months of Placebo administration (Treatment B - with prior run-in period)^a

Hormone	Period on Maca-GO or Placebo (before - and after crossover)	Start of the Trial	without prior run-in period		X	with prior run-in period		SE (±) of Mean (significance)
			After 1 month	After 2 month	↑	After 3 month	After 4 month
Hot flushes	PP-MM	9.3	2.2	10.2	X	2.5	0.6	0.58
	MM-PP	7.6	3.1	1.3	X	4.0	8.0	**
Excessive sweating	PP-MM	3.4	1.1	1.3	X	0.8	0.3	0.47
	MM-PP	2.9	0.9	0.5	X	1.5	3.0	**
Interrupted sleep pattern	PP-MM	1.6	0.2	2.4	X	0.8	0.0	0.33
	MM-PP	2.9	0.9	0.5	X	1.0	2.5	**
Nervousness	PP-MM	3.8	2.2	2.0	X	2.5	1.4	0.45
	MM-PP	4.9	2.0	1.8	X	2.3	1.8	*
Depression	PP-MM	1.4	0.7	0.9	X	0.9	0.1	0.19
	MM-PP	1.3	0.4	0.4	X	0.4	0.4	*
Loosing body balance	PP-MM	0.6	0.1	0.1	X	0.1	0.0	0.18
	MM-PP	1.0	0.3	0.3	X	0.5	0.4	NS
General weakness	PP-MM	1.9	1.3	1.2	X	1.4	0.1	0.42
	MM-PP	2.1	1.4	1.0	X	2.0	0.5	NS
Joints pain	PP-MM	0.8	0.2	0.3	X	0.4	0.0	0.31
	MM-PP	1.1	0.2	0.5	X	0.5	0.1	NS
Headaches	PP-MM	1.2	0.6	0.3	X	0.4	0.0	0.54
	MM-PP	1.4	0.4	0.6	X	0.6	0.3	NS
Heart palpitations	PP-MM	1.3	0.2	0.1	X	0.1	0.4	0.23
	MM-PP	1.8	0.8	0.0	X	0.0	0.1	*
Numbness hands & legs	PP-MM	0.7	0.2	0.2	X	0.4	0.0	0.32
	MM-PP	1.0	0.3	0.5	X	0.4	0.0	NS

^aStatistical significance determined according to multiple Wilcoxon’s test.

^* P<0.05;

^** P<0.01;

NS, Not Significant.